Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers

Journal of Gastroenterology

Volumn 34, Issue SUPPL. 11, 1999, Pages 80-83

  Aoyama, N ^a   Tanigawara, Y ^a   Kita, T ^a   Sakai, T ^a   Shirakawa, K ^a   Shirasaka, D ^a   Kodama, F ^a   Okumura, K ^a   Kasuga, M ^a  

^a NONE

Author keywords

CYP2C19; Dual treatment; H. pylori eradication; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; OMEPRAZOLE; SUCRALFATE;

ALLELE; CAUCASIAN; CONFERENCE PAPER; DRUG METABOLISM; ETHNIC DIFFERENCE; EXON; GASTRITIS; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PATIENT CODING; PEPTIC ULCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SUCRALFATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033383967     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Van der Hulst RWM, Keller JJ, Rauws EAJ, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996;1:6-19.
2. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991;20:38-49.
3. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995;58:143-54.
4. De Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269: 15419-22.
5. De Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-8.
6. Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
7. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108: 1412-7.
8. Kleveland PM, Waldum HL, Brenna E, et al. Relationship between the efficacy of amoxicillin and intragastric pH for the treatment of Helicobacter pylori infection. Helicobacter 1997;2: 144-51.
9. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994;29 (suppl 201):16-23.
10. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
11. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacogenetics. Clin Pharmacol Ther 1992;52:160-9.